Clinical Trials Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Sjogren Syndrome Therapy
Study results from University Medical Center, Department of Rheumatology provide new insights into Sjogren syndrome therapy
August 27th, 2007
Research findings, "Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study," are discussed in a new report. "For invalidating symptoms in primary Sjögren's syndrome (pSS), there is still a need for easy-to-administer, cost-effective and well-tolerated systemic treatment. Leflunomide (LEF) is structurally unrelated to other immunomodulatory drugs and might be efficacious in pSS, given its characteristic immunoregulatory modes of action," researchers in Netherlands report. "To investigate the safety and efficacy of LEF in pSS in a phase II open-label pilot study. 15 patients with pSS with early and active disease received LEF 20 mg once...
Source: Clinical Trials Week (2007-08-27)
|
